维得利珠单抗联合糖皮质激素治疗老年重度溃疡性结肠炎的效果  

The Effect of Vedolizumab Combined with Glucocorticoids in the Treatment of Severe Ulcerative Colitis in Elderly Patients

作　　者：王子晨 WANG Zichen(Department of Gastroenterology,Liaoyang Central Hospital,Liaoyang City,Liaoyang,Liaoning 111000,China)

机构地区：[1]辽阳市中心医院消化内科,辽宁辽阳111000

出　　处：《中国医药指南》2025年第4期81-84,共4页Guide of China Medicine

摘　　要：目的观察老年重度溃疡性结肠炎患者联合维得利珠单抗与糖皮质激素治疗的疗效。方法选取辽阳市中心医院消化内科于2023年1月至2024年8月间治疗的86例老年重度溃疡性结肠炎患者作为研究对象,通过随机数字表法将其分为对照组和观察组,每组43例。对照组采用维得利珠单抗治疗,观察组采用维得利珠单抗+糖皮质激素治疗。治疗12周,比较两组治疗有效率、治疗前后的症状体征分数、二胺氧化酶(DAO)、D-乳酸(D-LA)、粪钙卫蛋白(FC)和粪便乳铁蛋白(FL)水平以及不良反应率。结果观察组的治疗有效率高于对照组(P<0.05)。观察组患者治疗后腹胀、腹痛、血便、大便性状症状评分低于对照组(P<0.05)。治疗后观察组DAO水平、D-LA水平、FC、FL水平均低于对照组(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论老年重度溃疡性结肠炎患者联合维得利珠单抗与糖皮质激素治疗的疗效肯定,能够有效改善患者症状体征,同时可更为有效地改善肠道屏障功能,降低炎症程度,并且不会增加不良反应。Objective To observe the efficacy of combination therapy with vedolizumab and glucocorticoids in elderly patients with severe ulcerative colitis.Methods A total of 86 elderly patients with severe ulcerative colitis treated by Department of Gastroenterology,Liaoyang Central Hospital from January 2023 to August 2024 were selected as the study objects,and were divided into control group and observation group by random number table method,with 43 cases in each group.The control group was treated with vederizumab,and the observation group was treated with vederizumab and glucocorticoid.After 12 weeks of treatment,the effective rate of treatment,the scores of symptoms and signs before and after treatment,the levels of diamine oxidase(DAO),D-lactic acid(D-LA),fecal calguarding protein(FC)and fecal lactoferrin(FL),and the rate of adverse reactions were compared between the two groups.Results The effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the symptom scores of abdominal distension,abdominal pain,bloody stool and stool traits in observation group were lower than those in control group(P<0.05).After treatment,the levels of DAO,D-LA,FC and FL in observation group were lower than those in control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions In elderly patients with severe ulcerative colitis,the combination of verderizumab and glucocorticoid therapy is effective,which can effectively improve the symptoms and signs of patients,and can more effectively improve the intestinal barrier function,reduce the degree of inflammation,and do not increase adverse reactions.

关 键 词：溃疡性结肠炎 重度 老年患者 维得利珠单抗 糖皮质激素 

分 类 号：R574.62[医药卫生—消化系统]